PDF(Pubmed)
Abstract：
UNASSIGNED: Many COVID-19 patients reveal a marked decrease in their lymphocyte counts, a condition that translates clinically into immunodepression and is common among these patients. Outcomes for infected patients vary depending on their lymphocytopenia status, especially their T-cell counts. Patients are more likely to recover when lymphocytopenia is resolved. When lymphocytopenia persists, severe complications can develop and often lead to death. Similarly, IL-10 concentration is elevated in severe COVID-19 cases and may be associated with the depression observed in T-cell counts. Accordingly, this systematic review and meta-analysis aims to analyze T-cell subsets and IL-10 levels among COVID-19 patients. Understanding the underlying mechanisms of the immunodepression observed in COVID-19, and its consequences, may enable early identification of disease severity and reduction of overall morbidity and mortality.
UNASSIGNED: A systematic search was conducted covering PubMed MEDLINE, Scopus, Web of Science, and EBSCO databases for journal articles published from December 1, 2019 to March 14, 2021. In addition, we reviewed bibliographies of relevant reviews and the medRxiv preprint server for eligible studies. Our search covered published studies reporting laboratory parameters for T-cell subsets (CD4/CD8) and IL-10 among confirmed COVID-19 patients. Six authors carried out the process of data screening, extraction, and quality assessment independently. The DerSimonian-Laird random-effect model was performed for this meta-analysis, and the standardized mean difference (SMD) and 95% confidence interval (CI) were calculated for each parameter.
UNASSIGNED: A total of 52 studies from 11 countries across 3 continents were included in this study. Compared with mild and survivor COVID-19 cases, severe and non-survivor cases had lower counts of CD4/CD8 T-cells and higher levels of IL-10.
UNASSIGNED: Our findings reveal that the level of CD4/CD8 T-cells and IL-10 are reliable predictors of severity and mortality in COVID-19 patients. The study protocol is registered with the International Prospective Register of Systematic Reviews (PROSPERO); registration number CRD42020218918.
UNASSIGNED: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020218918, identifier: CRD42020218918.
UNASSIGNED: A systematic search was conducted covering PubMed MEDLINE, Scopus, Web of Science, and EBSCO databases for journal articles published from December 1, 2019 to March 14, 2021. In addition, we reviewed bibliographies of relevant reviews and the medRxiv preprint server for eligible studies. Our search covered published studies reporting laboratory parameters for T-cell subsets (CD4/CD8) and IL-10 among confirmed COVID-19 patients. Six authors carried out the process of data screening, extraction, and quality assessment independently. The DerSimonian-Laird random-effect model was performed for this meta-analysis, and the standardized mean difference (SMD) and 95% confidence interval (CI) were calculated for each parameter.
UNASSIGNED: A total of 52 studies from 11 countries across 3 continents were included in this study. Compared with mild and survivor COVID-19 cases, severe and non-survivor cases had lower counts of CD4/CD8 T-cells and higher levels of IL-10.
UNASSIGNED: Our findings reveal that the level of CD4/CD8 T-cells and IL-10 are reliable predictors of severity and mortality in COVID-19 patients. The study protocol is registered with the International Prospective Register of Systematic Reviews (PROSPERO); registration number CRD42020218918.
UNASSIGNED: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020218918, identifier: CRD42020218918.
摘要：
未经证实：许多COVID-19患者的淋巴细胞计数明显下降，一种临床上转化为免疫抑制的疾病，在这些患者中很常见。感染患者的结果因其淋巴细胞减少状态而异，尤其是他们的T细胞计数.当淋巴细胞减少症解决时，患者更有可能康复。当淋巴细胞减少症持续存在时，严重的并发症可以发展，往往导致死亡。同样，在严重的COVID-19病例中，IL-10浓度升高，可能与T细胞计数中观察到的抑郁有关。因此，本系统评价和荟萃分析旨在分析COVID-19患者的T细胞亚群和IL-10水平.了解在COVID-19中观察到的免疫抑制的潜在机制及其后果，可以早期识别疾病的严重程度并降低总体发病率和死亡率。
未经授权：进行了涵盖PubMedMEDLINE的系统搜索，Scopus,WebofScience,和EBSCO数据库，用于2019年12月1日至2021年3月14日发表的期刊文章。此外,我们回顾了相关综述的参考书目和medRxiv预印本服务器的符合条件的研究.我们的搜索涵盖了已发表的研究，这些研究报告了确诊的COVID-19患者中T细胞亚群（CD4/CD8）和IL-10的实验室参数。六位作者进行了数据筛选的过程，提取,独立进行质量评估。DerSimonian-Laird随机效应模型用于此荟萃分析，并计算每个参数的标准化平均差(SMD)和95%置信区间(CI)。
UNASSIGNED：本研究共纳入了来自3大洲11个国家的52项研究。与轻度和幸存者COVID-19病例相比，重度和非存活病例的CD4/CD8T细胞计数较低,IL-10水平较高.
未经证实：我们的研究结果表明，CD4/CD8T细胞和IL-10水平是COVID-19患者严重程度和死亡率的可靠预测因子。研究方案已在国际前瞻性系统审查注册中心（PROSPERO）注册；注册号为CRD42020218918。
UNASSIGNED：https://www。crd.约克。AC.uk/prospro/display_record.php?ID=CRD42020218918，标识符：CRD42020218918。
未经授权：进行了涵盖PubMedMEDLINE的系统搜索，Scopus,WebofScience,和EBSCO数据库，用于2019年12月1日至2021年3月14日发表的期刊文章。此外,我们回顾了相关综述的参考书目和medRxiv预印本服务器的符合条件的研究.我们的搜索涵盖了已发表的研究，这些研究报告了确诊的COVID-19患者中T细胞亚群（CD4/CD8）和IL-10的实验室参数。六位作者进行了数据筛选的过程，提取,独立进行质量评估。DerSimonian-Laird随机效应模型用于此荟萃分析，并计算每个参数的标准化平均差(SMD)和95%置信区间(CI)。
UNASSIGNED：本研究共纳入了来自3大洲11个国家的52项研究。与轻度和幸存者COVID-19病例相比，重度和非存活病例的CD4/CD8T细胞计数较低,IL-10水平较高.
未经证实：我们的研究结果表明，CD4/CD8T细胞和IL-10水平是COVID-19患者严重程度和死亡率的可靠预测因子。研究方案已在国际前瞻性系统审查注册中心（PROSPERO）注册；注册号为CRD42020218918。
UNASSIGNED：https://www。crd.约克。AC.uk/prospro/display_record.php?ID=CRD42020218918，标识符：CRD42020218918。
